Mary Wilson
Well-known member
Available online 9 April 2021
In Press, Corrected Proof
https://doi.org/10.1016/S0140-6736(21)00675-9
Victoria JaneHallFFPH[SUP]a[/SUP][SUP]b[/SUP]*SarahFoulkesMSc[SUP]a[/SUP]*AndreCharlettPhD[SUP]a[/SUP][SUP]d[/SUP]AnaAttiMSc[SUP]a[/SUP]Edward JMonkMSc[SUP]a[/SUP]RuthSimmonsPhD[SUP]a[/SUP]EdgarWellingtonMSc[SUP]a[/SUP]Michelle JColeDBMS[SUP]a[/SUP]AyoubSaeiPhD[SUP]a[/SUP]BlancheOgutiMSc[SUP]a[/SUP][SUP]c[/SUP]KatieMunroMSc[SUP]a[/SUP]SarahWallaceMSc[SUP]a[/SUP]Peter DKirwanBSc[SUP]a[/SUP][SUP]e[/SUP]MadhumitaShrotriMSc[SUP]a[/SUP]AmoolyaVusirikalaMFPH[SUP]a[/SUP]SakibRokadiyaMRCP[SUP]a[/SUP]MeaghanKallMSc[SUP]a[/SUP]MariaZambonPhD[SUP]a[/SUP]?JLHeeney
Background
Increased understanding of whether individuals who have recovered from COVID-19 are protected from future SARS-CoV-2 infection is an urgent requirement. We aimed to investigate whether antibodies against SARS-CoV-2 were associated with a decreased risk of symptomatic and asymptomatic reinfection.
Methods
A large, multicentre, prospective cohort study was done, with participants recruited from publicly funded hospitals in all regions of England. All health-care workers, support staff, and administrative staff working at hospitals who could remain engaged in follow-up for 12 months were eligible to join The SARS-CoV-2 Immunity and Reinfection Evaluation study. Participants were excluded if they had no PCR tests after enrolment, enrolled after Dec 31, 2020, or had insufficient PCR and antibody data for cohort assignment. Participants attended regular SARS-CoV-2 PCR and antibody testing (every 2?4 weeks) and completed questionnaires every 2 weeks on symptoms and exposures. At enrolment, participants were assigned to either the positive cohort (antibody positive, or previous positive PCR or antibody test) or negative cohort (antibody negative, no previous positive PCR or antibody test). The primary outcome was a reinfection in the positive cohort or a primary infection in the negative cohort, determined by PCR tests. Potential reinfections were clinically reviewed and classified according to case definitions (confirmed, probable, or possible) and symptom-status, depending on the hierarchy of evidence. Primary infections in the negative cohort were defined as a first positive PCR test and seroconversions were excluded when not associated with a positive PCR test. A proportional hazards frailty model using a Poisson distribution was used to estimate incidence rate ratios (IRR) to compare infection rates in the two cohorts.
...
https://www.sciencedirect.com/science/article/pii/S0140673621006759
In Press, Corrected Proof
https://doi.org/10.1016/S0140-6736(21)00675-9
Victoria JaneHallFFPH[SUP]a[/SUP][SUP]b[/SUP]*SarahFoulkesMSc[SUP]a[/SUP]*AndreCharlettPhD[SUP]a[/SUP][SUP]d[/SUP]AnaAttiMSc[SUP]a[/SUP]Edward JMonkMSc[SUP]a[/SUP]RuthSimmonsPhD[SUP]a[/SUP]EdgarWellingtonMSc[SUP]a[/SUP]Michelle JColeDBMS[SUP]a[/SUP]AyoubSaeiPhD[SUP]a[/SUP]BlancheOgutiMSc[SUP]a[/SUP][SUP]c[/SUP]KatieMunroMSc[SUP]a[/SUP]SarahWallaceMSc[SUP]a[/SUP]Peter DKirwanBSc[SUP]a[/SUP][SUP]e[/SUP]MadhumitaShrotriMSc[SUP]a[/SUP]AmoolyaVusirikalaMFPH[SUP]a[/SUP]SakibRokadiyaMRCP[SUP]a[/SUP]MeaghanKallMSc[SUP]a[/SUP]MariaZambonPhD[SUP]a[/SUP]?JLHeeney
Background
Increased understanding of whether individuals who have recovered from COVID-19 are protected from future SARS-CoV-2 infection is an urgent requirement. We aimed to investigate whether antibodies against SARS-CoV-2 were associated with a decreased risk of symptomatic and asymptomatic reinfection.
Methods
A large, multicentre, prospective cohort study was done, with participants recruited from publicly funded hospitals in all regions of England. All health-care workers, support staff, and administrative staff working at hospitals who could remain engaged in follow-up for 12 months were eligible to join The SARS-CoV-2 Immunity and Reinfection Evaluation study. Participants were excluded if they had no PCR tests after enrolment, enrolled after Dec 31, 2020, or had insufficient PCR and antibody data for cohort assignment. Participants attended regular SARS-CoV-2 PCR and antibody testing (every 2?4 weeks) and completed questionnaires every 2 weeks on symptoms and exposures. At enrolment, participants were assigned to either the positive cohort (antibody positive, or previous positive PCR or antibody test) or negative cohort (antibody negative, no previous positive PCR or antibody test). The primary outcome was a reinfection in the positive cohort or a primary infection in the negative cohort, determined by PCR tests. Potential reinfections were clinically reviewed and classified according to case definitions (confirmed, probable, or possible) and symptom-status, depending on the hierarchy of evidence. Primary infections in the negative cohort were defined as a first positive PCR test and seroconversions were excluded when not associated with a positive PCR test. A proportional hazards frailty model using a Poisson distribution was used to estimate incidence rate ratios (IRR) to compare infection rates in the two cohorts.
...
https://www.sciencedirect.com/science/article/pii/S0140673621006759